BEVYXXA Drug Patent Profile

Which patents cover Bevyxxa, and what generic alternatives are available?

Bevyxxa is a drug marketed by Portola Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

DrugPatentWatch^® Generic Entry Outlook for Bevyxxa

Bevyxxa was eligible for patent challenges on June 23, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 8, 2026. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BEVYXXA

International Patents:	67
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	112
Patent Applications:	734
Drug Prices:	Drug price information for BEVYXXA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEVYXXA
DailyMed Link:	BEVYXXA at DailyMed

See drug prices for BEVYXXA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BEVYXXA

NDA:

208383

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for BEVYXXA

BEVYXXA is protected by six US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-001	Jun 23, 2017		DISCN	Yes	No
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017		DISCN	Yes	No
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017		DISCN	Yes	No				Y
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017		DISCN	Yes	No			Y

Expired US Patents for BEVYXXA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-001	Jun 23, 2017
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-001	Jun 23, 2017

EU/EMA Drug Approvals for BEVYXXA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Portola Pharma UK Limited	Dexxience	betrixaban	EMEA/H/C/004309Prevention of venous thromboembolism	Refused	no	no	no		2018-09-20

International Patents for BEVYXXA

When does loss-of-exclusivity occur for BEVYXXA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

Israel

Japan

New Zealand

Peru

Portugal

Russian Federation

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BEVYXXA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20080065662	NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR
South Korea	20020050784
Spain	2254385
Argentina	056787

Market Dynamics and Financial Trajectory for BEVYXXA

Last updated: February 20, 2026

What is BEVYXXA?

BEVYXXA (voclosporin) is an immunosuppressive drug approved by the U.S. Food and Drug Administration in 2021 for adult patients with active lupus nephritis. Developed by Aurinia Pharmaceuticals, it aims to improve clinical outcomes by inhibiting calcineurin, a key enzyme involved in T-cell activation.

How does BEVYXXA fit into the lupus nephritis treatment landscape?

Lupus nephritis, a severe complication of systemic lupus erythematosus, affects approximately 50,000-60,000 patients in the U.S. alone. The standard treatments include corticosteroids and immunosuppressants such as mycophenolate mofetil and cyclophosphamide. BEVYXXA offers an alternative with a different mechanism of action, targeting a specific immune pathway.

Market Size and Growth Potential

Parameter	Data
Global lupus nephritis market (2022)	Approximately $1.2 billion (estimated)
U.S. market share (2022)	Estimated at $540 million
Projected compound annual growth rate (CAGR) (2023-2028)	8% to 10%
Number of eligible patients in the U.S.	50,000 - 60,000 (active cases)

The lupus nephritis market is expected to grow with rising disease awareness, increased diagnosis, and expanding treatment options. BEVYXXA's commercial prospects depend on its ability to capture a significant share from existing immunosuppressants and potential off-label uses.

Market Dynamics

Competitive Landscape

BEVYXXA faces competition from established treatments:

• Mycophenolate mofetil
• Cyclophosphamide
• Azathioprine
• Rituximab (off-label use)
• Belimumab (approved for systemic lupus erythematosus but not specific to nephritis)

While these drugs have limitations such as toxicity and variable efficacy, BEVYXXA's targeted mechanism offers improvements in safety and potentially better renal outcomes.

Pricing and Reimbursement

The drug is priced approximately $87,500 annually per patient (2021 pricing). Reimbursement depends on insurance coverage, with note that typical coverage rates are around 70-80%. Human costs, including monitoring and management of side effects, impact overall revenue.

Adoption Barriers

• Limited long-term safety data
• Competitive inertia from established therapies
• Need for physician education on new treatment protocols
• Formulation and administration routes (oral vs. infusion)

Regulatory and Manufacturing Factors

Pre-approval data indicated a favorable safety profile. The manufacturing process involves complex peptidic synthesis, which might impact margins. The company’s capacity to scale production influences supply and cost.

Revenue Trajectory

Current Revenue (2022-2023)

Aurinia generated approximately $78 million in BEVYXXA sales in 2022, driven primarily by initial launches in the U.S. and select international markets.

Forecast (2023-2028)

Year	Projected Revenue	Assumptions
2023	$120 million	Increased market uptake; expanded payer coverage
2024	$180 million	Greater physician familiarity; formulary placements
2025	$250 million	Growth in eligible patient population; additional indications

Factors influencing revenue growth include:

• Market penetration rate
• Off-label use expansion
• Competitive developments
• New clinical data demonstrating efficacy or safety improvements

Risks

• Slow adoption due to conservative physician prescribing
• Market entry of biosimilars or generics
• Pricing pressures from payers

Strategic Opportunities

• Clinical trials exploring combination therapies
• Expansion into other autoimmune conditions
• Real-world evidence supporting safety and efficacy
• Strategic partnerships with payers and health systems

Key Takeaways

• BEVYXXA addresses a significant unmet need in lupus nephritis, with a market of roughly $1.2 billion globally.
• The drug's revenue forecast indicates strong growth potential, reaching approximately $250 million by 2025.
• Market adoption depends on physician acceptance, safety profile, and reimbursement policies.
• Competition remains formidable, with established immunosuppressants continuing as primary options.
• Strategic expansion and clinical data will influence long-term market dynamics.

FAQs

1. What factors could limit BEVYXXA’s market penetration?
Physician familiarity with existing therapies, safety profile concerns, and reimbursement hurdles could slow adoption.

2. How does BEVYXXA compare price-wise to competitors?
At around $87,500 per year, BEVYXXA is priced comparable to some immunosuppressants, but payer negotiations may impact net revenue.

3. Are there off-label uses that could boost sales?
Potential off-label use in other autoimmune diseases presents opportunities but remains unconfirmed pending clinical trials.

4. What is the timeline for expanding indications?
Clinical trials for other autoimmune conditions are ongoing or in planning stages; approval timelines depend on data outcomes.

5. How could biosimilar or generic entrants impact BEVYXXA?
Entry of biosimilars could lead to price compression, reducing revenue growth unless differentiation is maintained through clinical benefits.

---

References

[1] Aurinia Pharmaceuticals. (2022). BEVYXXA (voclosporin) prescribing information.
[2] MarketsandMarkets. (2023). Lupus nephritis treatment market by region and therapy.
[3] IQVIA. (2022). Global autoimmune disease market report.
[4] FDA. (2021). Approval letter for BEVYXXA.